Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer

Yang, Xiaoqian; Iyer, Arun K.; Singh, Amit; Milane, Lara; Choy, Edwin; Hornicek, Francis J.; Amiji, Mansoor M.; Duan, Zhenfeng

doi:10.1007/s11095-014-1602-1

Cited by 77 publications

(59 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Second, (CSO-PEI)HA could target CD44 receptors overexpressed in various cancer because the HA can specifically bind to CD44. 31,32 A previous study had also reported that internalization of antibody-targeted nanoparticles was extremely dependent on the surface concentration of the ligand. 33 We observed that the (CSO-PEI/siRNA)HA had better selectivity to endometriotic lesion than CSO-PEI/siRNA.…”

mentioning

confidence: 99%

Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation

Zhao¹,

Cheng²,

Yan³

et al. 2016

IJN

View full text Add to dashboard Cite

To identify a new drug candidate for treating endometriosis which has fewer side effects, a new polymeric nanoparticle gene delivery system consisting of polyethylenimine-grafted chitosan oligosaccharide (CSO-PEI) with hyaluronic acid (HA) and small interfering RNA (siRNA) was designed. There was no obvious difference in sizes observed between (CSO-PEI/siRNA)HA and CSO-PEI/siRNA, but the fluorescence accumulation in the endometriotic lesion was more significant for (CSO-PEI/siRNA)HA compared with CSO-PEI/siRNA due to the specific binding of HA to CD44. In addition, the (CSO-PEI/siRNA)HA nanoparticle gene therapy significantly decreased the endometriotic lesion sizes with atrophy and degeneration of the ectopic endometrium. The epithelial cells of ectopic endometrium from rat models of endometriosis showed a significantly lower CD44 expression than control after treatment with (CSO-PEI/siRNA)HA. Furthermore, observation under an electron microscope showed no obvious toxic effect on the reproductive organs. Therefore, (CSO-PEI/siRNA)HA gene delivery system can be used as an effective method for the treatment of endometriosis.

show abstract

mentioning

confidence: 99%

Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation

Zhao¹,

Cheng²,

Yan³

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…Focus has now shifted towards downregulating the transcription of P-gp with siRNA [87,120,121] or microRNA [122,123] using nanoparticle (NP) drug delivery systems [124] . Hyaluronic acid based nanoparticles can effectively target CD44+ ovarian cancer cells and downregulate P-gp and increase intracellular concentration of paclitaxel.…”

Section: Evading P-gp (Nanoparticle Drug Delivery Systems)mentioning

confidence: 99%

“…Hyaluronic acid based nanoparticles can effectively target CD44+ ovarian cancer cells and downregulate P-gp and increase intracellular concentration of paclitaxel. High CD44+ expression in ovarian cancer cells is related to metastasis, therefore this cell-specific approach has the potential to improve the cell sensitivity in ovarian cancer patients with poor prognosis [120,121] . Encapsulation drugs in liposomal nanoparticles show promising results in the clinical setting.…”

Section: Evading P-gp (Nanoparticle Drug Delivery Systems)mentioning

confidence: 99%

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Jaramillo¹,

Saig²,

Cloos³

et al. 2018

CDR

View full text Add to dashboard Cite

P-glycoprotein (ABCB1), multidrug resistance protein-1 (ABCC1) and breast cancer resistance protein (ABCG2) belong to the ATP-binding cassette (ABC) superfamily of proteins that play an important physiological role in protection of the body from toxic xenobiotics and endogenous metabolites. Beyond this, these transporters determine the toxicity profile of many drugs, and confer multidrug resistance (MDR) in cancer cells associated with a poor treatment outcome of cancer patients.It has long been hypothesized that inhibition of ABC drug efflux transporters will increase drug accumulation and thereby overcome MDR, but until now no approved inhibitor of these transporters is available in the clinic. In this review we present molecular strategies to overcome this type of drug resistance and discuss for each of these strategies their promising value or indicate underlying reasons for their limited success.

show abstract

“…HA can also be conjugated to lipids ( Figure 3B) or polymers (Figure 5B) using chemical linkers [36][37][38][39][40][41]. HA-DOPE conjugate can be obtained through the creation of an amide bond between the carboxylic groups of HA and the amino group of DOPE [37].…”

Section: Polyplexes and Lipoplexes Modifi Ed With Hyaluronic Acidmentioning

confidence: 99%

“…HA-PEI conjugates can form complexes with siRNA, miRNA, or pDNA by electrostatic interaction between negatively charged nucleic acids and the positively charged PEI moiety of the HA-PEI conjugate ( Figure 5B) [41][42][43][44][45][46][47]. HA-PEI conjugates formed via an amide bond between the carboxyl groups of HA and the amine groups of branched PEI showed speci ic gene silencing ef icacy by the addition of siRNA/HA-PEI polyplexes into tumor cells [42].…”

Section: Polyplexes and Lipoplexes Modifi Ed With Hyaluronic Acidmentioning

confidence: 99%

Progress in the development of Lipoplex and Polyplex modified with Anionic Polymer for efficient Gene Delivery

Hattori¹

2017

J Genet Med Gene Ther

View full text Add to dashboard Cite

Nucleic acid-based therapy has become an increasingly important strategy for treating a variety of human diseases. In systemic therapy, a therapeutic gene must be delivered effi ciently to its target tissues without side effects. To deliver a therapeutic gene such as plasmid DNA (pDNA) or small interfering RNA (siRNA) to target tissues by systemic administration, cationic carriers such as cationic liposomes and polymers have been commonly used as a non-viral vector. However, the binary complex of therapeutic gene and cationic carrier must be stabilized in the blood circulation by avoiding agglutination with blood components, because electrostatic interactions between positively charged complexes and negatively charged erythrocytes can cause agglutination, and the agglutinates contribute to high entrapment of the therapeutic genes in the highly extended lung capillaries. One promising approach for overcoming this problem is modifi cation of the surface of cationic complexes with anionic biodegradable polymers such as hyaluronic acid, chondroitin sulfate, or polyglutamic acid. As another approach, we recently developed a sequential injection method of anionic polymer and cationic liposome/therapeutic gene complex (cationic lipoplex) for delivery of a therapeutic gene into the liver or liver metastasis. In this review, we describe recent advances in the delivery of therapeutic genes by lipid-and polymerbased carrier systems using anionic polymers.

show abstract

Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer

Cited by 77 publications

References 47 publications

Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation

Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation

How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

Progress in the development of Lipoplex and Polyplex modified with Anionic Polymer for efficient Gene Delivery

Contact Info

Product

Resources

About